Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27403589 | 1.00 | CYP2D6 (0.65) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL2599502 | 0.98 | CYP2D6 (0.63) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL12609561 | 0.84 | — | — | |
| SCHEMBL12609564 | 0.84 | — | — | |
| SCHEMBL357358 | 0.79 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL8538844 | 0.79 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL1626963 | 0.79 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL4536932 | 0.79 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL17455406 | 0.79 | SLC6A2 (1.00) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL20052872 | 0.79 | SLC6A2 (1.00) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | claimed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | disclosed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| CN-1075812-C | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2001-12-05 | — | — | CN | disclosed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | PNMT, OPRL1, OPRM1 | CYP2D6 319/4885SLC6A2 5/4885SLC6A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.